<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05793060</url>
  </required_header>
  <id_info>
    <org_study_id>DTH: 23001</org_study_id>
    <nct_id>NCT05793060</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine Versus Dexamethasone as Adjuvants to Bupivacaine for Intermediate Cervical Plexus Block</brief_title>
  <official_title>Dexmedetomidine Versus Dexamethasone as Adjuvants to Bupivacaine for Ultrasound-guided Intermediate Cervical Plexus Block in Patients Undergoing Thyroidectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Damanhour Teaching Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Damanhour Teaching Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Many thyroidectomy patients suffer from postoperative pain that could delay early&#xD;
      hospital discharge and place a significant burden on both the patient and the healthcare&#xD;
      team. Bilateral intermediate cervical plexus block (ICPB) provides good analgesia for neck&#xD;
      surgery, including thyroidectomy. However, the duration of a single-shot nerve block is&#xD;
      usually short. Therefore, adjuvants are used in peripheral nerve blocks.&#xD;
&#xD;
      Objectives: To compare the safety and efficacy of dexmedetomidine versus dexamethasone as&#xD;
      adjuvants to bupivacaine in ultrasound-guided intermediate cervical plexus block in patients&#xD;
      undergoing total thyroidectomy under general anesthesia.&#xD;
&#xD;
      Patients and Methods: This is a randomized, double-blind, phase four, prospective clinical&#xD;
      trial; carried out on 60 patients, who were candidates for total thyroidectomy under general&#xD;
      anesthesia at our hospital. Patients were randomly allocated into two equal groups; group A,&#xD;
      received bilateral ICPB with isobaric bupivacaine plus dexmedetomidine, and group B, received&#xD;
      bilateral ICPB with isobaric bupivacaine plus dexamethasone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2022</start_date>
  <completion_date type="Anticipated">April 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median and Range of Numeric Pain Rating Scale (NPRS) score [(median (range)]</measure>
    <time_frame>24 hours after the end of the operation</time_frame>
    <description>NPRS measures the severity of pain, it is a 11 point scale from 0-10; where 0=No pain and 10=Worst possible pain ( At post anesthesia care unit (PACU), then every 2 hours till 24 hours)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean and Standard deviation of Numeric Pain Rating Scale (NPRS) score (mean±SD)</measure>
    <time_frame>24 hours after the end of the operation</time_frame>
    <description>NPRS measures the severity of pain, it is a 11 point scale from 0-10; where 0=No pain and 10=Worst possible pain ( At PACU, then every 2 hours till 24 hours)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants and Percentage of Drug-related side effects</measure>
    <time_frame>24 hours after the end of the operation</time_frame>
    <description>Number of participants and Rate of: Bradycardia, Hypotension, Dysrhythmia, and Postoperative nausea and vomiting (PONV)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Analgesia</condition>
  <arm_group>
    <arm_group_label>Group A (n=30)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexmedetomidine group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (n=30)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine Hydrochloride</intervention_name>
    <description>Dexmedetomidine 50 Mcg</description>
    <arm_group_label>Group A (n=30)</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone Phosphate</intervention_name>
    <description>Dexamethasone 4 mg</description>
    <arm_group_label>Group B (n=30)</arm_group_label>
    <other_name>Dexamethasone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) physical status ≤ II&#xD;
&#xD;
          -  Age from 21 to 60 years&#xD;
&#xD;
          -  Body Mass Index (BMI) ≤ 35 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ASA physical status &gt; II&#xD;
&#xD;
          -  Age &lt; 21 years or &gt; 50 years&#xD;
&#xD;
          -  BMI &gt; 35 kg/m2&#xD;
&#xD;
          -  Bronchial asthma&#xD;
&#xD;
          -  Chronic obstructive pulmonary disease&#xD;
&#xD;
          -  Restrictive lung diseases&#xD;
&#xD;
          -  Sick sinus syndrome&#xD;
&#xD;
          -  Sinus bradycardia&#xD;
&#xD;
          -  Hypertension&#xD;
&#xD;
          -  Chronic hypotension&#xD;
&#xD;
          -  Ischemic heart disease&#xD;
&#xD;
          -  Coagulopathies&#xD;
&#xD;
          -  Hepatic insufficiency&#xD;
&#xD;
          -  Renal insufficiency&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Peripheral neuropathy&#xD;
&#xD;
          -  Thyroid malignancy&#xD;
&#xD;
          -  Hyperthyroidism&#xD;
&#xD;
          -  Substernal goiter&#xD;
&#xD;
          -  Patients on beta-blockers&#xD;
&#xD;
          -  Patients using pacemakers&#xD;
&#xD;
          -  Alcohol or drug abuse&#xD;
&#xD;
          -  Allergy to the study drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed M Shaat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Damanhour Teaching Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed M Shaat, MD</last_name>
    <phone>00201223482709</phone>
    <email>ahmedshaat99@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Damanhour Teaching Hospital</name>
      <address>
        <city>Damanhūr</city>
        <state>El-Beheira</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed M Shaat, MD</last_name>
      <phone>00201223482709</phone>
      <email>ahmedshaat99@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2022</verification_date>
  <study_first_submitted>March 17, 2023</study_first_submitted>
  <study_first_submitted_qc>March 29, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2023</study_first_posted>
  <last_update_submitted>March 29, 2023</last_update_submitted>
  <last_update_submitted_qc>March 29, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cervical plexus block</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Thyroidectomy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

